NCT00309946View on ClinicalTrials.gov

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Advanced Malignant MesotheliomaEpithelial MesotheliomaLocalized Malignant MesotheliomaRecurrent Malignant MesotheliomaSarcomatous Mesothelioma
Interventions
DRUG

cediranib maleate

Given orally

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00309946 - Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter